As a result, papers were retracted. Universities launched investigations. Researchers lost positions and reputations. Meanwhile, billions of dollars and decades of effort flowed into an amyloid-centered model.

Scientific fraud is not a victimless crime.

When flawed science influences research priorities, patients and families pay the price.

Most people do not follow academic journals. Instead, they follow hope.

Families trusted that breakthroughs were around the corner. Patients waited. Caregivers sacrificed. Researchers promised that removing amyloid plaque would finally change the course of Alzheimer's disease.

Unfortunately, those promises produced far less than many people expected.

The Biggest Lesson Was Not About Fraud

Although the scandals received enormous attention, the most important lesson had nothing to do with misconduct alone.

Instead, the larger lesson involved a scientific assumption.

For decades, researchers believed that amyloid plaque caused Alzheimer's disease. Therefore, removing plaque became the primary goal.

That approach seemed logical.

After all, amyloid plaques appear in the brains of Alzheimer's patients. Consequently, many experts assumed that plaque itself represented the driving force behind the disease.

However, assumptions and outcomes are not always the same.

Despite tremendous advances in imaging and drug development, the clinical results failed to match expectations.

Today, many scientists recognize that Alzheimer's disease involves inflammation, metabolism, vascular function, immune regulation, toxins, hormones, sleep, and numerous other factors.

In other words, the story turned out to be much more complicated than originally believed.

The Swollen Ankle Problem

Imagine someone severely sprains an ankle.

Soon afterward, swelling develops.

Suppose a treatment successfully reduces the swelling but leaves the damaged ligaments untouched.

The ankle might look better. However, the injury remains.

No orthopedic surgeon would confuse reducing swelling with repairing damaged tissue.

The same principle applies to Alzheimer's disease.

Amyloid plaque may be important. However, importance and causation are not the same thing.

Amyloid may represent a biomarker, contributor, or response mechanism. Nevertheless, the most important question is not:

How do we remove amyloid?

The better question is:

Why is the brain producing amyloid in the first place?

If inflammation, insulin resistance, toxins, infections, sleep disorders, vascular disease, hormonal imbalances, or immune dysfunction are stressing the brain, then removing plaque alone cannot solve those underlying problems.

Trying to treat Alzheimer's disease by focusing only on plaque may resemble putting an ice pack on a swollen ankle while ignoring the torn ligaments underneath.

Leqembi® and Kisunla® Changed the Conversation, But Not the Outcome

The arrival of monoclonal antibody drugs such as Leqembi® and Kisunla® represented a remarkable scientific achievement.

These drugs clearly demonstrated that amyloid plaque can be removed.

However, removing plaque and restoring cognitive function are not the same thing.

Although these drugs produced statistically measurable slowing of decline, the practical difference for many families remained surprisingly small.

The disease continued to progress.

Memory problems continued.

Daily challenges continued.

Loss of independence continued.

Families do not care about plaque. Families care about names, conversations, recognizing grandchildren, quality of life, and independence.

Most importantly, families care about improvement.

Simply slowing decline by an amount that may not even be noticeable in everyday life does not represent the breakthrough patients were promised.

Patients Cannot Afford to Waste Time

Time matters.

Cognitive decline is progressive.

Every month lost represents brain function that may never be regained.

Therefore, patients and families face an important question.

If a therapy produces little noticeable improvement while the disease continues to progress, how much valuable time disappears in the process?

Patients can always pursue infusion therapies later. However, time lost during progressive cognitive decline cannot be recovered.

Consequently, pursuing therapies that offer only modest slowing may carry an enormous opportunity cost.

Patients deserve to know that.

Why One Drug Was Never Likely to Solve Alzheimer's Disease

Alzheimer's disease rarely behaves like a single-target condition.

Instead, cognitive decline often involves multiple contributors occurring at the same time.

• Chronic inflammation
• Insulin resistance
• Sleep apnea
• Hormonal imbalances
• Mold exposure
• Heavy metals
• Environmental toxins
• Nutritional deficiencies
• Vascular disease
• Immune dysfunction
• Chronic stress
• Brain network dysfunction

Every patient presents with a unique combination. Therefore, expecting one drug to correct every possible combination becomes increasingly difficult to justify.

Alzheimer's disease behaves more like a systems failure than a drug deficiency.

That is why the future of Alzheimer's care is unlikely to come from chasing one target. Instead, it will come from identifying the many factors that may be driving cognitive decline in each individual patient.

What the EVANTHEA Trial Changed

For decades, success meant slowing decline.

The EVANTHEA Precision Medicine Trial changed that definition.

Participants improved.

Not merely slowed.

Improved.

That distinction changes everything.

Improvement and slowing are fundamentally different goals.

For years, patients were taught to accept slower decline as success. EVANTHEA challenged that assumption.

The study addressed multiple contributors simultaneously. Researchers focused on inflammation, metabolism, sleep, exercise, nutrition, stress, hormones, and cognitive stimulation.

Instead of targeting one pathway, the study used a systems-based approach.

Importantly, the strongest outcomes reported in EVANTHEA exceeded the benefits reported with monoclonal antibody therapies.

That comparison deserves attention because it represents a profound shift in thinking.

Precision Medicine Represents a Different Philosophy

Precision Medicine asks a different question.

Rather than asking:

Which drug treats Alzheimer's disease?

Precision Medicine asks:

What factors are stressing this person's brain?

That distinction matters.

At the Carroll Institute, the Carroll Cognitive Method™ combines Precision Medicine, Functional Medicine, and Functional Neurology.

Together, these approaches help identify biological contributors affecting brain health while supporting neuroplasticity and brain network function.

The goal is not simply to slow decline.

The goal is to improve function whenever improvement remains possible.

Neuroplasticity Changes the Conversation

For years, many experts believed that damaged brains could not improve.

Modern neuroscience tells a different story.

The brain possesses an extraordinary ability called neuroplasticity.

Neuroplasticity allows the brain to adapt, reorganize, and strengthen neural pathways.

At the Carroll Institute, we often describe neuroplasticity as the turbocharger of Precision Medicine.

However, neuroplasticity works best when inflammation decreases, metabolism improves, sleep strengthens, and the brain receives targeted stimulation.

Therefore, identifying root causes matters.

Healthy brain networks require healthy conditions.

What the Alzheimer's Research Controversies Really Taught Us

The controversies taught us something much bigger than the dangers of scientific misconduct.

They taught us that Alzheimer's disease is far more complex than anyone originally imagined.

They taught us that chasing plaque is not the same as restoring brain health.

They taught us that removing smoke is not the same as extinguishing the fire.

Most importantly, they taught us that patients deserve more than modest slowing.

Patients deserve answers.

Patients deserve hope.

Patients deserve a search for the factors affecting their brain.

And perhaps the most important lesson of all is this:

The future of Alzheimer's care is unlikely to come from chasing plaque. Instead, it will come from understanding why the brain is struggling in the first place.

Next Steps

If you or someone you love has Mild Cognitive Impairment, Alzheimer's disease, memory loss, or cognitive decline, we encourage you to schedule a discovery phone call with the Carroll Institute.

Together, we can explore whether the Carroll Cognitive Method™ may be appropriate for your situation.

Sources

• EVANTHEA Precision Medicine Trial — ClinicalTrials.gov
  https://clinicaltrials.gov/study/NCT05894954
• Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications — Journal of Alzheimer's Disease
  https://pubmed.ncbi.nlm.nih.gov/37807782/
• Neuroplasticity and the Brain — NCBI Bookshelf
  https://www.ncbi.nlm.nih.gov/books/NBK20367/
• What Happens to the Brain in Alzheimer's Disease? — National Institute on Aging
  https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease
• Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development
  https://pubmed.ncbi.nlm.nih.gov/36442193/
• Alzheimer's Disease and the Immune System: A Comprehensive Overview
  https://pmc.ncbi.nlm.nih.gov/articles/PMC12035277/
• Carroll Cognitive Method™
  https://thecarrollinstitute.com/tci-recode-program
• Dr. Garland Glenn
  https://thecarrollinstitute.com/about-dr-garland-glenn

Medical Disclaimer

This information is provided for educational purposes only and is not intended as medical advice. Individual outcomes vary. No specific result can be guaranteed. Patients should consult a qualified healthcare professional regarding their individual medical situation.

Reviewed by: Dr. Garland Glenn, DC, PhD, IFM, AFMC

Location: Sarasota, Florida

Last Updated: June 20, 2026